Literature DB >> 22678379

Should preclinical studies be registered?

Jonathan Kimmelman, James A Anderson.   

Abstract

Mesh：

Year:  2012        PMID： 22678379      PMCID： PMC4516408          DOI： 10.1038/nbt.2261

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  10 in total

Review 1.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

Review 2.  Neutralization of tumor necrosis factor in preclinical models of sepsis.

Authors:  José A Lorente; John C Marshall
Journal:  Shock       Date:  2005-12       Impact factor: 3.454

3.  Clinical trial registration: looking back and moving ahead.

Authors:  Christine Laine; Catherine De Angelis; Tony Delamothe; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; Paul C Hébert; Richard Horton; Sheldon Kotzin; Ana Marusic; Peush Sahni; Torben V Schroeder; Harold C Sox; Martin B Van der Weyden; Freek W A Verheugt
Journal:  Ann Intern Med       Date:  2007-06-04       Impact factor: 25.391

4.  Issues in the registration of clinical trials.

Authors:  Deborah A Zarin; Nicholas C Ide; Tony Tse; William R Harlan; Joyce C West; Donald A B Lindberg
Journal:  JAMA       Date:  2007-05-16       Impact factor: 56.272

5.  Shining a light on trial data.

Authors: 
Journal:  Nat Biotechnol       Date:  2012-05-07       Impact factor: 54.908

6.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

Authors:  R S Obach; J G Baxter; T E Liston; B M Silber; B C Jones; F MacIntyre; D J Rance; P Wastall
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

Review 7.  Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?

Authors:  Janet Clarke; Christopher Hurst; Pauline Martin; John Vahle; Rafael Ponce; Barbara Mounho; Shawn Heidel; Laura Andrews; Theresa Reynolds; Joy Cavagnaro
Journal:  Regul Toxicol Pharmacol       Date:  2007-08-24       Impact factor: 3.271

8.  Publication bias in reports of animal stroke studies leads to major overstatement of efficacy.

Authors:  Emily S Sena; H Bart van der Worp; Philip M W Bath; David W Howells; Malcolm R Macleod
Journal:  PLoS Biol       Date:  2010-03-30       Impact factor: 8.029

9.  Effects of NXY-059 in experimental stroke: an individual animal meta-analysis.

Authors:  P M W Bath; L J Gray; A J G Bath; A Buchan; T Miyata; A R Green
Journal:  Br J Pharmacol       Date:  2009-04-27       Impact factor: 8.739

10.  Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis.

Authors:  Joseph S Ross; Tony Tse; Deborah A Zarin; Hui Xu; Lei Zhou; Harlan M Krumholz
Journal:  BMJ       Date:  2012-01-03
  10 in total
  33 in total

1.  Assessing risk/benefit for trials using preclinical evidence: a proposal.

Authors:  Jonathan Kimmelman; Valerie Henderson
Journal:  J Med Ethics       Date:  2015-10-13       Impact factor: 2.903

2.  The use of systematic reviews and reporting guidelines to advance the implementation of the 3Rs.

Authors:  Marc T Avey; Nicole Fenwick; Gilly Griffin
Journal:  J Am Assoc Lab Anim Sci       Date:  2015-03       Impact factor: 1.232

3.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research.

Authors:  Nathalie Percie du Sert; Viki Hurst; Amrita Ahluwalia; Sabina Alam; Marc T Avey; Monya Baker; William J Browne; Alejandra Clark; Innes C Cuthill; Ulrich Dirnagl; Michael Emerson; Paul Garner; Stephen T Holgate; David W Howells; Natasha A Karp; Stanley E Lazic; Katie Lidster; Catriona J MacCallum; Malcolm Macleod; Esther J Pearl; Ole H Petersen; Frances Rawle; Penny Reynolds; Kieron Rooney; Emily S Sena; Shai D Silberberg; Thomas Steckler; Hanno Würbel
Journal:  Exp Physiol       Date:  2020-07-14       Impact factor: 2.969

4.  The ARRIVE guidelines 2.0: updated guidelines for reporting animal research.

Authors:  Nathalie Percie du Sert; Viki Hurst; Amrita Ahluwalia; Sabina Alam; Marc T Avey; Monya Baker; William J Browne; Alejandra Clark; Innes C Cuthill; Ulrich Dirnagl; Michael Emerson; Paul Garner; Stephen T Holgate; David W Howells; Natasha A Karp; Stanley E Lazic; Katie Lidster; Catriona J MacCallum; Malcolm Macleod; Esther J Pearl; Ole H Petersen; Frances Rawle; Penny Reynolds; Kieron Rooney; Emily S Sena; Shai D Silberberg; Thomas Steckler; Hanno Würbel
Journal:  J Physiol       Date:  2020-07-14       Impact factor: 5.182

Review 5.  The challenge and promise of anti-epileptic therapy development in animal models.

Authors:  Michele Simonato; Amy R Brooks-Kayal; Jerome Engel; Aristea S Galanopoulou; Frances E Jensen; Solomon L Moshé; Terence J O'Brien; Asla Pitkanen; Karen S Wilcox; Jacqueline A French
Journal:  Lancet Neurol       Date:  2014-08-10       Impact factor: 44.182

6.  Late, never or non-existent: the inaccessibility of preclinical evidence for new drugs.

Authors:  C A Federico; B Carlisle; J Kimmelman; D A Fergusson
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

Review 7.  Epilepsy therapy development: technical and methodologic issues in studies with animal models.

Authors:  Aristea S Galanopoulou; Merab Kokaia; Jeffrey A Loeb; Astrid Nehlig; Asla Pitkänen; Michael A Rogawski; Kevin J Staley; Vicky H Whittemore; F Edward Dudek
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

8.  Quality and validity of large animal experiments in stroke: A systematic review.

Authors:  Leona Kringe; Emily S Sena; Edith Motschall; Zsanett Bahor; Qianying Wang; Andrea M Herrmann; Christoph Mülling; Stephan Meckel; Johannes Boltze
Journal:  J Cereb Blood Flow Metab       Date:  2020-06-23       Impact factor: 6.200

Review 9.  Issues for new antiepilepsy drug development.

Authors:  Michele Simonato; Jacqueline A French; Aristea S Galanopoulou; Terence J O'Brien
Journal:  Curr Opin Neurol       Date:  2013-04       Impact factor: 5.710

10.  Biosafety data as confidential business information.

Authors:  Kaare M Nielsen
Journal:  PLoS Biol       Date:  2013-03-05       Impact factor: 8.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.